Keros Therapeutics, Inc. - Common Stock (KROS)
CUSIP: 492327101
Q3 2024 13F Holders as of 30 Sep 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 19,711,307
- Total 13F shares
- 34,948,467
- Share change
- +3,322,339
- Total reported value
- $2,029,993,469
- Put/Call ratio
- 12%
- Price per share
- $58.07
- Number of holders
- 162
- Value change
- +$197,656,348
- Number of buys
- 92
- Number of sells
- 60
Quarterly Holders Quick Answers
What is CUSIP 492327101?
CUSIP 492327101 identifies KROS - Keros Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 492327101:
Top shareholders of KROS - Keros Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
24%
|
4,719,760
|
$215,693,033 | — | 30 Jun 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
13%
|
2,513,244
|
$114,855,253 | — | 30 Jun 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
8.9%
|
1,757,120
|
$80,300,383 | — | 30 Jun 2024 | |
| ALKEON CAPITAL MANAGEMENT LLC |
13F
|
Company |
8.1%
|
1,598,907
|
$73,070,050 | — | 30 Jun 2024 | |
| Darwin Global Management, Ltd. |
13F
|
Company |
7.7%
|
1,525,902
|
$68,772,403 | — | 30 Jun 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
6.4%
|
1,268,734
|
$57,981,144 | — | 30 Jun 2024 | |
| STATE STREET CORP |
13F
|
Company |
6.2%
|
1,221,376
|
$55,816,883 | — | 30 Jun 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
6%
|
1,187,910
|
$54,288,000 | — | 30 Jun 2024 | |
| BRAIDWELL LP |
13F
|
Company |
5%
|
982,209
|
$44,886,951 | — | 30 Jun 2024 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
4.6%
|
899,077
|
$41,087,819 | — | 30 Jun 2024 | |
| TCG Crossover Management, LLC |
13F
|
Company |
4.5%
|
879,344
|
$40,186,021 | — | 30 Jun 2024 | |
| Woodline Partners LP |
13F
|
Company |
3.9%
|
775,845
|
$35,456,117 | — | 30 Jun 2024 | |
| Holocene Advisors, LP |
13F
|
Company |
3.5%
|
688,326
|
$31,456,498 | — | 30 Jun 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
3.4%
|
679,580
|
$31,063,079 | — | 30 Jun 2024 | |
| Redmile Group, LLC |
13F
|
Company |
2.8%
|
552,506
|
$25,249,524 | — | 30 Jun 2024 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
2.8%
|
548,916
|
$25,085,461 | — | 30 Jun 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
2.6%
|
521,447
|
$23,830,128 | — | 30 Jun 2024 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
2.5%
|
499,208
|
$22,813,806 | — | 30 Jun 2024 | |
| S.c.a. Candriam |
13F
|
Individual |
2.2%
|
441,855
|
$20,191,831 | — | 30 Jun 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.1%
|
410,484
|
$18,759,119 | — | 30 Jun 2024 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
2%
|
400,214
|
$18,289,780 | — | 30 Jun 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
2%
|
392,956
|
$17,958,089 | — | 30 Jun 2024 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
1.9%
|
378,807
|
$17,311,480 | — | 30 Jun 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.9%
|
370,350
|
$16,924,991 | — | 30 Jun 2024 | |
| Opaleye Management Inc. |
13F
|
Company |
1.9%
|
367,500
|
$16,794,750 | — | 30 Jun 2024 | |
| Avidity Partners Management LP |
13F
|
Company |
1.7%
|
343,200
|
$15,684,240 | — | 30 Jun 2024 | |
| MORGAN STANLEY |
13F
|
Company |
1.7%
|
335,669
|
$15,340,074 | — | 30 Jun 2024 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
1.5%
|
298,170
|
$13,626,423 | — | 30 Jun 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
1.2%
|
236,488
|
$10,807,502 | — | 30 Jun 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.2%
|
230,000
|
$10,511,000 | — | 30 Jun 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
1.2%
|
227,628
|
$10,402,600 | — | 30 Jun 2024 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
1.1%
|
221,600
|
$10,127,120 | — | 30 Jun 2024 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
1%
|
198,627
|
$9,077,254 | — | 30 Jun 2024 | |
| EcoR1 Capital, LLC |
13F
|
Company |
0.95%
|
187,500
|
$8,568,750 | — | 30 Jun 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.91%
|
178,994
|
$8,180,026 | — | 30 Jun 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.89%
|
175,695
|
$8,029,262 | — | 30 Jun 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.82%
|
161,715
|
$7,389,694 | — | 30 Jun 2024 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
0.8%
|
157,633
|
$7,203,828 | — | 30 Jun 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.76%
|
150,462
|
$6,876,113 | — | 30 Jun 2024 | |
| Granahan Investment Management, LLC |
13F
|
Company |
0.74%
|
144,976
|
$6,625,403 | — | 30 Jun 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.63%
|
124,113
|
$5,671,965 | — | 30 Jun 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.6%
|
118,388
|
$5,410,333 | — | 30 Jun 2024 | |
| WCM INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.59%
|
116,544
|
$5,252,638 | — | 30 Jun 2024 | |
| READYSTATE ASSET MANAGEMENT LP |
13F
|
Company |
0.58%
|
113,823
|
$5,201,711 | — | 30 Jun 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.55%
|
107,780
|
$4,925,546 | — | 30 Jun 2024 | |
| Jennifer Lachey |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
103,855
mixed-class rows
|
$4,307,079 | — | 15 Jul 2022 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.45%
|
88,636
|
$4,050,665 | — | 30 Jun 2024 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
0.43%
|
85,000
|
$3,884,500 | — | 30 Jun 2024 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.42%
|
82,352
|
$3,763,484 | — | 30 Jun 2024 | |
| SUPERSTRING CAPITAL MANAGEMENT LP |
13F
|
Company |
0.38%
|
74,288
|
$3,394,962 | — | 30 Jun 2024 |
Institutional Holders of Keros Therapeutics, Inc. - Common Stock (KROS) as of Q3 2024
As of 30 Sep 2024,
Keros Therapeutics, Inc. - Common Stock (KROS) was held by
162 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
34,948,467 shares.
The largest 10 holders included
FMR LLC, BlackRock, Inc., ALKEON CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, Darwin Global Management, Ltd., PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, ORBIMED ADVISORS LLC, Point72 Asset Management, L.P., and TCG Crossover Management, LLC.
This page lists
162
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
150
Q3 2024 holders
162
Holder diff
12
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 Value $ | Q3 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.